We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+16.53%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
+$173M
Cap. Flow
+$55.4M
Cap. Flow %
3.14%
Top 10 Hldgs %
80.46%
Holding
31
New
5
Increased
4
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$100M
2
BLUE
bluebird bio
BLUE
+$20.5M
3
SVRA icon
Savara
SVRA
+$11.1M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$10.2M
5
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$7.56M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$114M

Sector Composition

Rank Sector Weight
1 Healthcare 92.43%
2 Financials 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$429M 24.3%
5,831,307
-1,450,000
-20% -$114M
AVIR icon
2
Atea Pharmaceuticals
AVIR
$405M
$347M 19.64%
5,615,659
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.23B
$115M 6.52%
3,979,292
– –
DVAX
4
DELISTED
Dynavax Technologies
DVAX
$107M 6.07%
10,895,773
– –
ANNX icon
5
Annexon
ANNX
$885M
$90.2M 5.11%
3,241,628
– –
PHVS icon
6
Pharvaris
PHVS
$2.43B
$89M 5.04%
+3,180,601
New +$100M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$78.8M 4.46%
3,080,237
– –
CCCC icon
8
C4 Therapeutics
CCCC
$406M
$60.7M 3.44%
1,642,209
– –
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$59.8M 3.39%
147,827
+10,000
+7% +$4.85M
SLDB icon
10
Solid Biosciences
SLDB
$907M
$43.9M 2.48%
528,661
+57,971
+12% +$6.41M
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$43.3M 2.45%
578,504
– –
NRIX icon
12
Nurix Therapeutics
NRIX
$2.66B
$39.9M 2.26%
1,284,314
– –
CNST
13
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$32.7M 1.86%
1,400,000
– –
APTX
14
DELISTED
Aptinyx Inc. Common Stock
APTX
$26.7M 1.51%
8,891,758
– –
SVRA icon
15
Savara
SVRA
$1.18B
$24.2M 1.37%
11,622,598
+6,494,005
+127% +$11.1M
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$22.2M 1.25%
1,431,058
– –
SYRE icon
17
Spyre Therapeutics
SYRE
$9.26B
$21.4M 1.21%
108,000
– –
KYMR icon
18
Kymera Therapeutics
KYMR
$8.93B
$18.6M 1.06%
479,605
– –
XFOR icon
19
X4 Pharmaceuticals
XFOR
$444M
$18.2M 1.03%
70,651
+15,701
+29% +$4.13M
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.94B
$16.4M 0.93%
1,071,428
– –
BLUE
21
DELISTED
bluebird bio
BLUE
$16.2M 0.92%
+41,547
New +$20.5M
NAUT icon
22
Nautilus Biotechnolgy
NAUT
$114M
$13.8M 0.78%
1,000,000
– –
PNT
23
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$10.5M 0.6%
1,000,000
– –
RACB
24
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$10.3M 0.58%
+1,000,000
New +$10.2M
ARYD
25
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$7.33M 0.42%
+700,000
New +$7.56M
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2021 Portfolio in Review

As of Q1 2021, Bain Capital Life Sciences Investors held 31 positions worth $1.77B, up 11% from $1.59B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Bain Capital Life Sciences Investors deployed $55.4M of net new capital in Q1 2021, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Pharvaris: 3,180,601 shares worth $89M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $114M trimmed.

  • Bain Capital Life Sciences Investors's largest Q1 2021 buy was Pharvaris: 3,180,601 shares worth $89M.
  • Bain Capital Life Sciences Investors added most to Savara in Q1 2021, an estimated $11.1M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $114M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 80% of its $1.77B portfolio in Q1 2021.
  • Bain Capital Life Sciences Investors opened 5 new positions and closed 0 in Q1 2021.
  • Bain Capital Life Sciences Investors's portfolio value rose 11% quarter-over-quarter to $1.77B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2021, filed 17 May 2021.